Details of the Drug Combinations

General Information of This Drug (ID: DMYZFNH)

Drug Name
Sapanisertib   DMYZFNH
Synonyms INK-128; MLN0128; INK 128; INK128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; MLN-0128; JGH0DF1U03
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [2]
Therapeutic Class
Antiviral Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

19 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Alvespimycin hydrochloride + Sapanisertib DC2UGCJ Alvespimycin hydrochloride DD2 (Cell Line: DD2) [3]
Alvespimycin hydrochloride + Sapanisertib DCQOW40 Alvespimycin hydrochloride Hepatoblastoma (Cell Line: HB3) [4]
Azathioprine + Sapanisertib DCAFDOE Azathioprine Hodgkin lymphoma (Cell Line: L-1236) [3]
Doxorubicin + Sapanisertib DCBZ2BF Doxorubicin Hodgkin lymphoma (Cell Line: L-1236) [3]
Pelitinib + Sapanisertib DCKHUVA Pelitinib Hodgkin lymphoma (Cell Line: L-1236) [4]
Sapanisertib + Panobinostat DCMZ08Q Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Sapanisertib + Quinine DCP684M Quinine DD2 (Cell Line: DD2) [3]
Sapanisertib + Piperaquine DCP981J Piperaquine DD2 (Cell Line: DD2) [3]
Sapanisertib + Clindamycin DC3ZSBN Clindamycin Hepatoblastoma (Cell Line: HB3) [4]
Sapanisertib + Trametinib DCDTHE4 Trametinib Embryonal rhabdomyosarcoma (Cell Line: CTR) [4]
Sapanisertib + Trametinib DC4CMRP Trametinib Embryonal rhabdomyosarcoma (Cell Line: RD) [4]
Sapanisertib + Plicamycin DCMH3JA Plicamycin Hodgkin lymphoma (Cell Line: L-1236) [4]
Sapanisertib + Doxycycline DC0VCTF Doxycycline Hepatoblastoma (Cell Line: HB3) [4]
Sapanisertib + SCH 727965 DCQWO4H SCH 727965 Hodgkin lymphoma (Cell Line: L-1236) [4]
Sapanisertib + Cotellic DCPYCZJ Cotellic Embryonal rhabdomyosarcoma (Cell Line: Rh36) [4]
Sapanisertib + Cotellic DCPC72V Cotellic Embryonal rhabdomyosarcoma (Cell Line: CTR) [4]
Sapanisertib + Cotellic DCML66X Cotellic Embryonal rhabdomyosarcoma (Cell Line: RD) [4]
Sapanisertib + Bortezomib DCYZMHS Bortezomib Hodgkin lymphoma (Cell Line: L-1236) [4]
Sapanisertib + Naltrexone DC0UR4E Naltrexone Hepatoblastoma (Cell Line: HB3) [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 19 DrugCom(s)
5 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Letrozole + Sapanisertib DCHC556 Letrozole Breast Cancer [5]
MLN8237 + Sapanisertib DC12USM MLN8237 Malignant Neoplasms of Digestive Organs [6]
Osimertinib + Sapanisertib DCEGDDP Osimertinib Metastatic Lung Non-Small Cell Carcinoma [7]
Exemestane + Sapanisertib DC097MH Exemestane Breast Cancer [1]
Fulvestrant + Sapanisertib DC5O2AR Fulvestrant Breast Cancer [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02049957) Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer. U.S. National Institutes of Health.
2 Prevent COVID-19 Severity by Repurposing mTOR Inhibitors. 2 April 2020
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
5 ClinicalTrials.gov (NCT02619669) Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
6 ClinicalTrials.gov (NCT02812056) Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
7 ClinicalTrials.gov (NCT02503722) Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer